Bayer Hits Teva With Suit Over Levitra Patent

Law360, New York (July 1, 2009, 12:00 AM EDT) -- Teva Pharmaceutical Industries Ltd. is facing a suit by two Bayer AG units over the Israeli generics maker’s plans to launch a generic version of erectile dysfunction drug Levitra.

Bayer Schering Pharma and Bayer HealthCare Pharmaceuticals Inc., along with exclusive licensee Schering Corp., lodged a suit in the U.S. District Court for the District of Delaware on Wednesday after Teva submitted an abbreviated new drug application seeking federal approval to make and sell a drug containing vardenafil hydrochloride, the active ingredient in Levitra.

Teva notified Bayer...
To view the full article, register now.